MeRT® is a highly customized version of rTMS (repetitive Transcranial Magnetic Stimulation). The science and protocols of MeRT® are based on years of authoritative research published in some of the most prestigious scientific journals. Here are just some of these.
“This study suggests that rTMS is a potential treatment option for depression following TBI. Both 15 to 16 session and 30 to 38 session cohorts showed significant decreases in depression as measured by PHQ-9 following rTMS treatment. These findings support the use of rTMS in post-concussion depression treatment and highlight the need for more research on rTMS therapy following TBI.”
“Our findings uncover the neural mechanisms underlying the improvement in emotional well-being in TBI due to application of neuromodulation. The main effect of rTMS is to reduce emotional disorders and hence consequently it may improve cognitive and executive functions.”
“Our results are consistent with studies showing improved cognitive functioning in TBI following a unilateral or bilateral rTMS protocol that used low frequency rTMS over the right DLPFC. Therefore, this stimulation site may be promising for improving cognitive recovery in TBI, especially when combined with cognitive rehabilitation.”
“Subjective measures of depression, sleep dysfunction, post-concussive symptoms (PCS), and executive function showed significant improvement with stimulation, retaining improved levels at two-week follow-up. EEG delta power exhibited elevation one week after stimulation cessation."
Neuromodulatory Interventions for Traumatic Brain Injury (November 2020)
“In this special issue of the Journal of Head Trauma Rehabilitation, we share with readers some of the latest advancements in neuromodulation specific to TBI, while providing the framework to further our understanding of how and why functional skills are likely improved. While neuromodulatory interventions can play a critical role in functional recovery for those with TBI, the heterogenous nature of TBI means that clinical implementation of neuromodulation will require understanding, at the individual and group levels, of how, when, and where to alter brain activity to support sustained recovery of sensory and higher order functions.”
“Evidence suggests that rTMS has the potential to be an efficacious therapeutic intervention for multiple symptoms after TBI, including depression, dizziness, central pain, and visual neglect."
“Case Report: A 37-year-old male with history of anxiety and bipolar depression incurred a TBI after a 60-foot fall. After his physical recovery, the patient had refractory depression. Eight months after the TBI event, he underwent a 6-week course of rTMS treatment and had a 70.8% improvement in mood symptoms by the end of the therapy as indicated by the Patient Health Questionnaire-9, transitioning from severe to mild depression according to the scoring system. Clinical correlation during the months following conclusion of rTMS therapy showed no signs of remission or adverse side effects. The patient remains stable and lives independently 1 year after treatment with mood-stabilizing medications.
“Conclusion: This case provides evidence for successful treatment of refractory depressive symptoms after severe TBI with the addition of rTMS to psychotherapy and mood-stabilizing medications, supporting the safety and tolerability of this novel therapeutic approach. Further studies are needed to validate the contribution of rTMS for management of mood symptoms in patients with TBI.”